World AIDS DAY Part 5: EAVI2020’s research to a better future | Trial BCN03
Hi, I am EAVI2020 trial BCN03. Our trial takes place at IRSICAIXA with Christian Brander (Principal Investigator, IRSICAIXA) Beatriz Mothe (Principal Investigator, IRSICAIXA), working in collaboration with Rogier Sanders (Principal Investigator, AMC) and Dietmar Katinger (Principal Investigator, POLYMUN). Our trial focuses on a combined T- and B-cell, therapeutic HIV vaccine combining the HTI T cell vaccines with SOSIP envelope immunogens.
Our trial is primarily focusing on the safety of the intervention and whether the intervention can induce sustained virus control once antiretroviral therapy (ART) is stopped. What sets our trial apart is that this is the first therapeutic vaccine trial that combines potent T and B cell immunogens in a combination regimen. We are hoping that this trial will test whether the addition of a B cell immunogen component to a T cell vaccine regimen can improve post-vaccination virus control compared to a single component regimen.
Find out more about the other EAVI2020 trials taking place
Follow World AIDS Day campaigns on Twitter with #Rocktheribbon
To donate and show your support, go to the National AIDS Trust website
For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.
It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.